Last reviewed · How we verify
Standard course macrolide
Macrolides inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit.
Macrolides inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit. Used for Community-acquired pneumonia, Acute exacerbations of chronic bronchitis, Mild to moderate asthma.
At a glance
| Generic name | Standard course macrolide |
|---|---|
| Sponsor | UMC Utrecht |
| Drug class | Macrolide antibiotic |
| Target | 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
This action prevents the formation of peptide bonds between amino acids, ultimately leading to the death of the bacterial cell. Macrolides have a broad spectrum of activity and are effective against a wide range of Gram-positive and Gram-negative bacteria.
Approved indications
- Community-acquired pneumonia
- Acute exacerbations of chronic bronchitis
- Mild to moderate asthma
Common side effects
- Nausea
- Vomiting
- Abdominal pain
Key clinical trials
- Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors (PHASE2)
- Efficacy And Safety Of Azithromycin To Achieve Remissionin In Children With Steroid Sensitive Nephrotic Syndrome (PHASE1)
- Sanitation, Water, and Instruction in Face-washing for Trachoma I/II (PHASE3)
- Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy (PHASE2)
- Azithromycin as Adjunctive Treatment for Uncomplicated Severe Acute Malnutrition (PHASE4)
- Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer (PHASE1, PHASE2)
- STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection (NA)
- TAILORED Therapeutic Regime in Patients With Preterm Premature Rupture Of Membranes to Prolong Pregnancy, Improve Maternal and Neonatal Outcomes, and Reduce Antibiotic Burden (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard course macrolide CI brief — competitive landscape report
- Standard course macrolide updates RSS · CI watch RSS
- UMC Utrecht portfolio CI